The Benefits of Cannabidiol in Alzheimer's Disease Management

Overview of Alzheimer’s Disease and Treatment Options

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and alterations in behavior and personality. It is the most common cause of dementia, affecting millions worldwide. The disease is primarily marked by the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain (Patil et al., 2024). Despite extensive research, there remains no cure for AD, and current treatment options primarily focus on alleviating symptoms rather than addressing the underlying pathology.

The treatment landscape for Alzheimer’s has traditionally included cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, which aim to enhance cholinergic function by inhibiting the breakdown of acetylcholine. Additionally, memantine, an NMDA receptor antagonist, is used to moderate glutamatergic activity. However, these treatments are often limited by their side effects and only provide modest benefits in cognitive function (Patil et al., 2024).

Given the complexity of Alzheimer’s disease and its multifactorial nature, there is a growing interest in alternative therapeutic strategies, including the use of cannabinoids, particularly cannabidiol (CBD). CBD, a non-psychoactive component of cannabis, has shown promise in preclinical studies for its neuroprotective, anti-inflammatory, and antioxidant properties.

Cannabidiol: Mechanisms of Action in Alzheimer’s Treatment

Cannabidiol (CBD) exerts its effects through various mechanisms that may be beneficial in the context of Alzheimer’s disease. It interacts with multiple neurotransmitter systems, including the endocannabinoid system, which plays a crucial role in maintaining homeostasis in the central nervous system (Patil et al., 2024).

1. Neuroprotection: CBD has been shown to protect neurons from oxidative stress and inflammation, two critical factors in the pathogenesis of AD. Preclinical studies have demonstrated that CBD can reduce the production of reactive oxygen species (ROS) and inhibit neuroinflammation by modulating the activity of microglia, the brain’s immune cells (Patil et al., 2024).

2. Amyloid-Beta Accumulation: One of the hallmarks of Alzheimer’s disease is the accumulation of amyloid-beta plaques. CBD has been found to disrupt amyloid-beta aggregation and promote its clearance from the brain, potentially reducing the toxic effects associated with these plaques (Patil et al., 2024).

3. Calcium Homeostasis: CBD regulates intracellular calcium levels, which are often dysregulated in Alzheimer’s disease. This modulation helps prevent neuronal apoptosis and supports neuronal survival under conditions of stress (Patil et al., 2024).

4. Endocannabinoid Modulation: CBD enhances the endocannabinoid signaling by inhibiting the enzyme fatty acid amide hydrolase (FAAH), thus increasing the levels of endogenous cannabinoids like anandamide. This action has implications for enhancing neurogenesis and synaptic plasticity, both of which are crucial for cognitive function (Patil et al., 2024).

Cannabidiol’s Role in Reducing Amyloid-Beta Accumulation

Several studies have investigated CBD’s role in reducing amyloid-beta accumulation. In a systematic review, it was found that CBD could significantly reduce the levels of amyloid-beta in various in vitro and in vivo models of Alzheimer’s disease (Patil et al., 2024). The underlying mechanisms include:

• Inhibition of Amyloid Precursor Protein (APP): CBD has been shown to decrease the expression of APP, which is the precursor to amyloid-beta. By reducing APP levels, CBD may lower the overall amyloid-beta production.
• Promotion of Microglial Clearance: CBD enhances the phagocytic activity of microglia, facilitating the clearance of amyloid-beta aggregates from the brain. This action not only reduces the burden of amyloid-beta but also promotes a more favorable environment for neuronal health (Patil et al., 2024).

Table 1 summarizes key findings regarding the effects of CBD on amyloid-beta accumulation in various studies:

Exploring the Therapeutic Potential of Cannabidiol Variants

The therapeutic potential of CBD is not limited to its native form. Various CBD variants and analogs are being explored for their efficacy in Alzheimer’s disease management. These include:

• CBDV (Cannabidivarin): Similar to CBD, CBDV has shown potential in modulating neuroinflammation and has been associated with cognitive enhancement in animal models (Patil et al., 2024).
• THCV (Tetrahydrocannabivarin): THCV is another cannabinoid that may provide neuroprotective benefits and has been implicated in appetite regulation, potentially useful for managing weight-related issues in Alzheimer’s patients (Patil et al., 2024).
• CBDA (Cannabidiolic Acid): The acidic precursor to CBD, CBDA exhibits anti-inflammatory properties and has been shown to inhibit the aggregation of amyloid-beta, marking it as a potential candidate for AD treatment (Patil et al., 2024).

The combination of these cannabinoids, in what is often referred to as the “entourage effect,” may enhance their therapeutic efficacy when used in conjunction. This synergistic action could lead to better clinical outcomes compared to using CBD alone.

Implications for Future Research on Cannabidiol and Alzheimer’s

The findings from existing studies suggest that CBD and its variants hold significant promise for the management of Alzheimer’s disease. However, further research is imperative to confirm these effects in larger clinical trials. Key areas for future investigation include:

1. Long-Term Safety and Efficacy: Understanding the long-term effects of CBD on cognitive function and overall health in Alzheimer’s patients is crucial. Studies should focus on the optimal dosing and possible interactions with other medications commonly used in this population.

2. Mechanistic Studies: More detailed studies on the molecular pathways involved in CBD’s action against amyloid-beta accumulation and neuroinflammation are necessary to elucidate its therapeutic mechanisms (Patil et al., 2024).

3. Clinical Trials: Rigorous clinical trials should be conducted to explore the efficacy of CBD in diverse patient populations, including those with varying stages of Alzheimer’s disease. These trials should assess cognitive outcomes, quality of life metrics, and safety parameters associated with CBD use.

4. Exploration of Cannabinoid Combinations: Investigating the synergistic effects of CBD with other cannabinoids and terpenes may unveil new therapeutic strategies that could enhance treatment outcomes in Alzheimer’s patients.

FAQ

What is Cannabidiol (CBD)? CBD is a non-psychoactive compound found in cannabis plants, known for its potential therapeutic effects, including anti-inflammatory and neuroprotective properties.

How does CBD help in Alzheimer’s disease? CBD may help reduce amyloid-beta accumulation, protect neurons from oxidative stress, and modulate inflammatory responses in the brain, potentially slowing the progression of Alzheimer’s disease.

Are there any side effects of CBD? CBD is generally well-tolerated, but some individuals may experience side effects such as fatigue, diarrhea, and changes in appetite. It is essential to consult a healthcare provider before starting any new treatment.

Is CBD legal? The legality of CBD varies by country and state. In many places, CBD derived from hemp with low THC content is legal, while CBD from marijuana may have stricter regulations.

Can CBD replace traditional Alzheimer’s treatments? CBD should not replace conventional treatments for Alzheimer’s disease. Instead, it may serve as a complementary therapy that can enhance the overall treatment plan.

References

1. Patil, N., Patil, K., Jain, M., Mohammed, A., Yadav, A., Dhanda, P. S., Kole, C., Dave, K., Kaushik, P. (2024). A systematic study of molecular targets of cannabidiol in Alzheimer’s disease. Journal of Alzheimer’s Disease Reports

2. Khodadadi, H., Salles, É. L., Jarrahi, A., et al. (2021). Cannabidiol ameliorates cognitive function via regulation of IL-33 and TREM2 upregulation in a murine model of Alzheimer’s disease. Journal of Alzheimer’s Disease

3. De Paula Faria, D., Estessi de Souza, L., Duran, F. L. S., et al. (2022). Cannabidiol treatment improves glucose metabolism and memory in streptozotocin-induced Alzheimer’s disease rat model: a proof-of-concept study. International Journal of Molecular Sciences

4. Frandsen, A., Narayanasamy, P. (2022). Effect of cannabidiol on the neural glyoxalase pathway function and longevity of several C. elegans strains including a C. elegans Alzheimer’s disease model. ACS Chemical Neuroscience

5. Wang, Z., Zheng, P., Xie, Y., et al. (2021). Cannabidiol regulates CB1-pSTAT3 signaling for neurite outgrowth, prolongs lifespan, and improves healthspan in Caenorhabditis elegans of Aβ pathology models. FASEB Journal

6. Zhang, Y., Li, H., Jin, S., et al. (2022). Cannabidiol protects against Alzheimer’s disease in C. elegans via ROS scavenging activity of its phenolic hydroxyl groups. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2022.174829

7. Blasco-Benito, S., Seijo-Vila, M., Caro-Villalobos, M., Tundidor, I., Andradas, C., García-Taboada, E. (2018). Appraising the “Entourage Effect”: Antitumor Action of a Pure Cannabinoid versus a Botanical Drug Preparation in Preclinical Models of Breast Cancer. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2018.06.025

8. Morales, P., Hurst, D. P., Reggio, P. H. (2017). Molecular targets of the phytocannabinoids: A complex picture. In Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. Springer

9. Predescu, I. A., Jîjie, A. R., Pătraşcu, D., et al. (2025). Unveiling the Complexities of Medications, Substance Abuse, and Plants for Recreational and Narcotic Purposes: An In-Depth Analysis. Pharmacy. https://doi.org/10.3390/pharmacy13010007

10. Seth, T., Mishra, G. P., Chattopadhyay, A., et al. (2025). Microgreens: Functional Food for Nutrition and Dietary Diversification. Plants. https://doi.org/10.3390/plants14040526

11. Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence. (2024). Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1506142